CADTH's $50,000 Cost-Effectiveness Threshold: Fact or Fiction?

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

Previous Article
Biosimilar mAbs – a unique and distinct market (for the time being…?)
Biosimilar mAbs – a unique and distinct market (for the time being…?)

Next Article
Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?
Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

×

Speak to one of our experts today

First Name
Last Name
Company Name
Title
Country
Tell us how we can help
We'll be in touch shortly!
Error - something went wrong!
×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!